Rosuvastatin Dosage and Administration Guidelines for Hyperlipidemia

Dosing Guidelines Based on Patient Risk

The American College of Cardiology recommends moderate-intensity statin therapy with rosuvastatin 5-10 mg daily for primary prevention in patients aged 40-75 years without ASCVD, targeting an LDL-C reduction of ≥50% and a goal of <70 mg/dL 1, 3
For patients aged 40-75 years with additional ASCVD risk factors, high-intensity statin therapy with rosuvastatin 20-40 mg daily is recommended to reduce LDL-C by ≥50% and achieve an LDL-C goal of <70 mg/dL 1, 2
The American Heart Association recommends high-intensity statin therapy with rosuvastatin 20-40 mg daily for secondary prevention in patients with established ASCVD, targeting an LDL-C reduction of ≥50% and a goal of <55 mg/dL 2, 3

For patients with mild to moderate renal impairment, no dosage adjustment is needed, but for those with severe renal impairment, the starting dose should be 5 mg daily and not exceed 10 mg daily 4, 5
The American College of Cardiology recommends starting with 5 mg daily in Asian patients due to increased rosuvastatin plasma concentrations 6

When concomitantly using cyclosporine, the dose of rosuvastatin should not exceed 5 mg daily 7, 8

High-intensity statin therapy with rosuvastatin 20 mg is associated with a 36% relative increase in new-onset diabetes compared to placebo, according to the American Diabetes Association 9

Inadequate dose titration to achieve LDL-C goals, particularly in high-risk patients, can be avoided by following guidelines from the American College of Cardiology 1, 2
The American Heart Association recommends monitoring for adverse effects, especially muscle symptoms and elevated liver enzymes, when using high-intensity statin therapy 9